RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Beijing’s BeiGene reported that the National Medical Products Administration of China (NMPA, formerly known as CFDA or CDA) has accepted the company’s new drug application for tislelizumab, a PD-1 antibody, as a treatment for relapsed/refractory classical Hodgkin’s lymphoma. In a pivotal Phase II trial, tislelizumab produced an 87% overall response rate and a 61% complete response rate at a median of eight months follow up.
Source: China Biotoday
